The following ventures have been selected by the
INCATE Selection Committee
INVITRIS
Invitris developed the worldwide first platform technology to synthesize arbitrary phages within a single system, thus enabling full scalability of therapeutic phage isolation, modification, production, and application.
Myxobiotics
Myxobiotics is a start-up company discovering and developing novel antibiotics from natural products first isolated and characterized from myxobacteria.
smartbax
At smartbax we develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Tabrix
Developing novel anti-virulence agents for multi drug resistant TB and difficult to treat infectious diseases
Enzoxa
An innovative and selective treatment against stomach diseases caused by Helicobacter pylori
Rostra Therapeutics
Rostra Therapeutics is committed to bringing novel medicines to patients and clinicians delivering the power to restore health and save lives globally
Pedanius Therapeutics
Pedanius Therapeutics is developing RNAi therapeutics using two complimentary, bacterial delivery platform technologies silencing genes critical to bacterial growth and survival, thus introducing a versatile, novel modality into the battle against antimicrobial resistance
AMResolute
AMResolute is an early stage drug discovery and development company combating antibiotic-resistant bacterial infections through innovation, applying customised narrow spectrum antibiotics with a novel mode of action
Olgram
Olgram is a preclinical stage biotechnology company, creating new drugs to fight bacterial persisters (bacteria in a dormant state responsible for infectious relapses), by using an original approach on new chemical entities discovered in the sea
Fagoterapia
Fagoterapia LAB is the biotech producing and commercializing tailor-made drugs based on good viruses (phage) to cure antibiotic resistant infections. To develop its products FL will leverage on a technology platform based on a proprietary AI-algorithm and on a phage biobank
Oxford Silk Phage Technologies
OSPT is developing a new material integrating bacteriophage viruses, to produce medical implants reducing surgical site infections and the need for antibiotics
S. aureus α-hemolysin Inhibitors
The Helmholtz Centre for infection Research together with the Lead Discovery Center develop small molecule-based inhibitors of alpha-hemolysin to treat lung infections caused by Staphylococcus aureus
MyxoBiomedical
MyxoBiomedical develops a resistance-breaking macrolide antibiotic based on the myxobacterial natural product scaffold chlorotonil for the treatment of infections caused by MRSA/VRE
Kinzbio
Kinzbio is discovering phages that have been overlooked by standard discovery pipelines and have unique and previously unknown biological properties, leveraging their use for infection prevention
CC BIO
At CC Bio, we harness the power of synthetic biology to engineer and edit the microbiome with precision antimicrobials. Our goal is to eliminate microbiome-based disease in a potent, specific and prophylactic fashion, harmonising the relationship between eukaryotic and microbial cells
Xiretsa
Xiretsa is developing novel membrane-remodeling small-molecule antibiotics that evade resistance to address the greatest Gram-negative, Gram-positive, and Mycobacterial threats
Interface Biosciences
Interface Biosciences is developing a commensal-derived multifunctional RiPP for the treatment of bacterially-mediated inflammatory disease
Disperazol
With a new mechanism of action, a new class of compound and a new target, Disperazol is a robust, narrow-spectrum drug candidate with significant efficacy in inhibiting and dismantling Pseudomonas aeruginosa biofilms
VIKYNG – AI
VIKYNG – AI is a lead generation platform to improve innovations in AMR by combining Artificial Intelligence and a new class of antimicrobials called polypeptoids
Unison Medicines, Inc
Unison Medicines develops small molecule inhibitors of RecA to be used in combination with other front-line antibiotic agents.
MetalloBio
MetalloBio is a deep-tech antimicrobials development company which is advancing 2 completely new classes of compounds, based on a proprietary inorganic chemistry platform with broad-spectrum against all WHO pathogens of concern; showing little to no emergence of genetic resistance, effective against bacteria with various resistance mechanisms, and showing no antagonism with existing antibiotics tested to date
PhageOne Theranostics
Building an integrated company for Phage Therapy
Paerublock
Paerublock develops non-traditional small molecules targeting elastase (LasB) from Pseudomonas aeruginosa as novel antibiotic therapeutics
CorA
The University Hospital Bonn together with Helmholtz Centre for Infection research develops the natural compound Corallopyronin A for difficult-to-treat Gram-positive infections, with funding from DZIF
Puray
Utilizing UV light, Puray provides the world’s first permanently disinfected medical tubing, offering superior infection prevention for patients
ARIVA Med
ARIVA Med focuses on developing innovative anti-infectives to combat antimicrobial resistance. Its lead program, the Epimutilins, features novel compounds with strong antibacterial activity against priority pathogens, unaffected by resistance to other antibiotic classes, addressing critical global health threats identified by the WHO and CDC.
Oxford SimCell Ltd.
SimCells® are genome-free bacteria produced by switchable enzymatic shearing, which inactivates bacterial cells while preserving immunogenic cell surface features, offering a new approach to creating safe and effective whole-cell vaccines against bacterial pathogens
Phiogen Pharmaceuticals
The goal the project is to further develop IND enabling data for a series of high-performing bacteriophages to be formulated into a single, fixed product for the treatment of MDR pathogens in recurrent urinary tract infections (rUTI) and someday be applied in clinical settings.
NanA
A new serotype-independent immunostimulatory agent to protect the brain from pneumococcal infections
Resist – AB
Small synthetic, narrow-spectrum resistance-breaking antibiotics against Acinetobacter baumannii.
A&J Science
Leveraging its proprietary platform technology on marine natural products to develop highly effective antibiotics against hard-to-treat and intractable bacterial diseases.
Microplate Dx
Microplate Dx is an award-winning spinout company specializing in developing rapid antibiotic susceptibility testing diagnostics.
Theralia AB
Theralia is developing the first oligonucleotide-based antibiotics, Therapeutic Oligonucleotides Activated by Nucleases (TOUCANs), for the targeted delivery of antibacterial molecules into infection area that enables a safer and more effective treatment for bacterial infections.
Paralos Bioscience
Paralos Bioscience is developing a first-in-class phage-drug conjugate drug delivery platform technology with the goal of significantly improving the therapeutic index for drugs across many classes to tackle the most imminent global healthcare challenges.
Omnicin Therapeutics
Omnicin Therapeutics is developing metal-containing inhalation therapies to resensitize multi-resistant bacteria to antibiotics”.
Brigid Bio
Providing next generation immunotherapy for life-threatening, invasive fungal infections.
The following ventures were selected
at INCATE pitch events
Limmatech Biologics
LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation vaccines for the prevention of life-threatening diseases.
iFast Diagnostics
an ultra-fast, low cost, high-throughput Antimicrobial Susceptibility Test suitable for all bacterial infections
Puray
Utilizing UV light, Puray provides the world’s first permanently disinfected medical tubing, offering superior infection prevention for patients